The Psychedelic Access and European Alliance (PAREA) has launched an appeal to European Union institutions and Member States for psychedelic-assisted therapies in Europe.
Germany’s Federal Ministry of Education and Research (BMBF) has provided a grant of €2.6m for a study exploring the efficacy of psilocybin as a treatment for...
Sintalica Bioscience has received, through the University of Messina, authorisations from the Italian Ministry of Health pertaining to its drug development programme.
Awakn Life Sciences has announced the signing of a five-year lease to open a larger Awakn Clinics Oslo.
Cybin’s CYB004-E Phase 1 trial evaluating DMT has completed dosing for four out of five participant cohorts.
The European Psychiatric Association (EPA) is joining the Psychedelic Access and Research European Alliance (PAREA) as a full member.
Psyence Group has completed an export of psilocybin to Psilo Pharma from its federally licensed ISO22000 certified production facility in Southern Africa, through its research partner...
Psychedelic Health speaks to the founder of the Psychedelic Access and Research European Alliance (PAREA), Tadeusz Hawrot, about how the organisation aims to facilitate discussions around...
Clerkenwell Health is expanding its pan-European advisory board with the addition of Dr David Erritzoe, Dr Dea Siggaard Stenbæk, Dr Kim Kuypers and Dr James Stone...
Last week Italy’s Constitutional Court blocked the country’s campaign calling for the decriminalisation of psychotropic substance cultivation.
